News

Pfizer and BioNTech announced that they intend to advance multiple SARS-CoV-2 vaccine candidates into human clinical testing, with the first clinical trials potentially beginning by late April. The two companies began their collaboration focused on developing a vaccine for...

CirrusDx validated and will commercialize the Allplex 2019-nCoV Assay, a real-time Reverse Transcriptase PCR test developed by Seegene, a South Korea-based global leader in multiplex molecular diagnostics. Cirrus Dx, an infectious disease laboratory and diagnostics company, received Emergency Use Authorization...

CENTOGENE , a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, and the Cologne-based blockchain start-up Ubirch announced a joint solution for the successful fight...

Merck, a leading science and technology company, and The Jenner Institute announced that the Jenner Institute has laid the foundation for large-scale production of its Covid-19 vaccine candidate, ChAdOx1 nCoV-19. With patients enrolled for clinical trials for this vaccine, rapid...

Moderna, a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, has entered an agreement for a commitment of up to $483 million from the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office...

Roche announced the development and upcoming launch of its Elecsys® Anti-SARS-CoV-2 serology test to detect antibodies in people who have been exposed to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that causes the COVID-19 disease. Antibody testing is central...

Kaneka Corporation (President: Minoru Tanaka) has reached an agreement with FUJIFILM Corporation (President: Kenji Sukeno) to supply drug substances for anti-influenza drug, Avigan® Tablet (general name: favipiravir), for the novel coronavirus disease (referred to below as COVID-19). While COVID-19 continues...